Supplemental Digital Content 1. Subject disposition. PCV13=13-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine. *All-available immunogenicity population was defined as all subjects who had at least 1 valid and determinate assay result related to the proposed analysis. bDiscontinued before the blood draw visit after the PPSV23 dose, except for “other” who discontinued after the blood draw visit after the PPSV23 dose because of pregnancy. cSubjects could be excluded for >1 reason; reasons for exclusion from evaluable immunogenicity population include not eligible for study, CD4 HIV window (most recent CD4 count >180 days), received <2 doses of PCV13 in the sequence assigned; no valid assay result after doses of PCV13 and PPSV23 for any serotype.